profit from every $100 of sales.
$0$100
Standard BioTools
$0.69+9.15% today
-38.6% in 1 year
1-year low $0.601-year high $1.68
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Standard BioTools sold, what it kept, and what it did with the cash.
Sales went from $97.9 million in 2022 to $85.3 million in 2025, with -$74.9 million of profit last year.
SalesProfit
Standard BioTools vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Standard BioTools | No profit yet | ||
 Boston Scientific | 22.0× · Fair price | ||
 Koninklijke Philips | 30.0× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 29.1× · Fair price |
AI analysis
An AI analyst reads Standard BioTools's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 98 | 106 | 91 | 85 | |
| 37 | 50 | 45 | 43 | |
| -103 | -63 | -87 | -93 | |
| -174 | -54 | -70 | -86 | |
| -190 | -75 | -139 | -75 | |
| -2.43 | -0.94 | -0.52 | -0.20 | |
| 37.8% | 47.4% | 49.3% | 49.9% | |
| -104.8% | -59.3% | -95.6% | -109.3% | |
| -194.1% | -70.2% | -152.6% | -87.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 390 | 323 | 612 | 568 |
| Cash | 81 | 52 | 167 | 121 |
| Total debt | 103 | 98 | 31 | 31 |
| Total liabilities | 472 | 471 | 141 | 143 |
| -81 | -148 | 472 | 424 | |
| 78 | 79 | 353 | 382 | |
| -703.2% | – | -13.7% | -16.8% | |
| 233.3% | 50.4% | -29.4% | -17.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -89 | -43 | -143 | -74 | |
| 4 | 3 | 8 | 8 | |
| -93 | -46 | -152 | -83 | |
| Dividends paid | – | – | – | – |
| 1 | 5 | 40 | 0 | |
| 15 | 13 | 32 | 30 |
Valuation
- –
- –
- –
- 0.7×
- 3.2×
- –
- –
- -30.2%
- -27.3%
- 0.0%
Profitability
- 49.9%
- -109.3%
- -87.8%
- -109.0%
- -6.4%
- -164.0%
- 17.3%
- 12.2%
- -11.7%
- 34.5%
Growth
- −4.5%
- –
- +45.6%
- –
- +49.8%
Financial health
- -1.1×
- 0.05
- 4.6%
- -2,906.3×
- 12.36
- 11.92
- 0.10
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 30%of 948
Bottom 3%of 871
Bottom 10%of 868
Bottom 2%of 985
What analysts expect
- Average price target
- $3.25
- Range
- $3.25 – $3.25
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.02 | -0.02 | +0.0% |
| Feb 24, 2026 | 0.06 | -0.03 | +300.0% |
| Nov 4, 2025 | -0.04 | -0.03 | −60.0% |
| Aug 11, 2025 | -0.04 | -0.04 | +0.0% |
| May 6, 2025 | -0.04 | -0.04 | +0.0% |
| Feb 26, 2025 | -0.05 | -0.07 | +28.6% |
| Oct 30, 2024 | -0.05 | -0.08 | +37.5% |
| Jul 31, 2024 | -0.08 | -0.06 | −33.3% |
News
Rocket Lab shares dip after the company’s ‘defining’ quarter misses the markMarketWatch · Nov 9, 2026The 2027 tax brackets are out. See what the standard deduction and SALT tax breaks will be.MarketWatch · Nov 7, 2026Rocket Lab Stock Has Lost About 70% From Its Record. Is It Finally a Buy?Yahoo Finance · Nov 6, 2026Why Rocket Lab Stock Plunged 15% in October and Why Its Decline Might Be Short-LivedYahoo Finance · Nov 5, 2026Rocket Lab's Backlog Is $2.36 Billion -- More Than Double Its 2026 Revenue -- and the Stock Still Fell 38% This Month. Here's the Disconnect.Yahoo Finance · Oct 31, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
70Pass
Philip Fisher
38No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
44No pass
Terry Smith
47No pass
Questions about Standard BioTools
Is Standard BioTools a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Standard BioTools AI analysis
What does Standard BioTools do?
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It is in Medical - Devices.
Does Standard BioTools pay a dividend?
No. Standard BioTools does not pay a dividend at the moment.
Is Standard BioTools stock halal?
No. Standard BioTools does not pass our halal screen: its cash and confirmed interest-bearing investments are 44% of its market value, at or above the 33% limit. How we check
How has Standard BioTools stock done over the past year?
Down 38.6% over the past twelve months, to $0.69. It traded between $0.60 and $1.68 and is 58.7% below its high.
Who are Standard BioTools's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Standard BioTools's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.